{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:03:24Z","timestamp":1791932604342,"version":"4.3.4"},"reference-count":82,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Daratumumab (Dara) is the first monoclonal antibody introduced into clinical practice to treat multiple myeloma (MM). It currently forms the backbone of therapy regimens in both newly diagnosed (ND) and relapsed\/refractory (RR) patients. However, previous reports indicated an increased risk of infectious complications (ICs) during Dara-based treatment. In this study, we aimed to determine the profile of ICs in MM patients treated with Dara-based regimens and establish predictors of their occurrence. Methods: This retrospective, real-life study included MM patients treated with Dara-based regimens between July 2019 and March 2024 at our institution. Infectious events were evaluated using the Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results: The study group consisted of a total of 139 patients, including 49 NDMM and 90 RRMM. In the RR setting, the majority (60.0%) of patients received the Dara, bortezomib, and dexamethasone (DVd) regimen, whereas ND patients were predominantly (98%) treated with the Dara, bortezomib, thalidomide, and dexamethasone (DVTd) regimen. Overall, 55 patients (39.6%) experienced ICs. The most common IC was pneumonia (37.5%), followed by upper respiratory tract infections (26.8%). Finally, twenty-five patients had severe ICs (grade \u2265 3) and required hospitalization, and eight patients died due to ICs. In the final multivariable model adjusted for setting (ND\/RR) and age, hemoglobin level (OR 0.77, 95% CI: 0.61\u20130.96, p = 0.0037), and Eastern Cooperative Oncology Group (ECOG) &gt;1 (OR 4.46, 95% CI: 1.63\u201312.26, p = 0.0037) were significant factors influencing severe IC occurrence. Additionally, we developed predictive models using the J48 decision tree, gradient boosting, and random forest algorithms. After conducting 10-fold cross-validation, these models demonstrated strong performance in predicting the occurrence of pneumonia during treatment with daratumumab-based regimens. Conclusions: Simple clinical and laboratory assessments, including hemoglobin level and ECOG scale, can be valuable in identifying patients vulnerable to infections during Dara-based regimens, facilitating personalized prophylactic strategies.<\/jats:p>","DOI":"10.3390\/cancers16213709","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:52:54Z","timestamp":1730713974000},"page":"3709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-2583","authenticated-orcid":false,"given":"Damian","family":"Mikulski","sequence":"first","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland"},{"name":"Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin Kamil","family":"K\u0119dzior","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4621-6247","authenticated-orcid":false,"given":"Grzegorz","family":"Mirocha","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-0317","authenticated-orcid":false,"given":"Katarzyna","family":"Jerzmanowska-Piechota","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland"},{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0857-4816","authenticated-orcid":false,"given":"\u017baneta","family":"Witas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Wo\u017aniak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Pawlak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2879-7985","authenticated-orcid":false,"given":"Kacper","family":"Ko\u015bcielny","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Ko\u015bny","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland"},{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland"},{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Go\u0142os","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland"},{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"},{"name":"Department of General Hematology, Copernicus Memorial Hospital, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Fendler","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"G\u00f3ra-Tybor","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland"},{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple Myeloma Epidemiology and Survival, a Unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: A First-in-Class CD38 Monoclonal Antibody for the Treatment of Multiple Myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab Monotherapy in Patients with Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_10","unstructured":"Blimark, C.H., Carlson, K., Day, C., Einarsdottir, S., Juliusson, G., Karma, M., Knut-Bojanowska, D., Larfors, G., Turesson, I., and Villegas-Scivetti, M. (Haematologica, 2020). Risk of Infections in Multiple Myeloma. A Population-Based Study on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry, Haematologica, early view."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s002770100330","article-title":"Risk Factors for Early Death in Patients Undergoing Treatment for Multiple Myeloma","volume":"80","author":"Murakami","year":"2001","journal-title":"Ann. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple Myeloma and Infections: A Population-Based Study on 9253 Multiple Myeloma Patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofac574","DOI":"10.1093\/ofid\/ofac574","article-title":"Cumulative Incidence and Relative Risk of Infection in Patients with Multiple Myeloma Treated with Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-Analysis","volume":"9","author":"Vassilopoulos","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Glar\u00eda, E., and Valledor, A.F. (2020). Roles of CD38 in the Immune Response to Infection. Cells, 9.","DOI":"10.3390\/cells9010228"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of Daratumumab on Natural Killer Cells and Impact on Clinical Outcomes in Relapsed or Refractory Multiple Myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-134923","article-title":"Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM)","volume":"136","author":"Zweegman","year":"2020","journal-title":"Blood"},{"key":"ref_17","unstructured":"(2024, July 24). Obwieszczenie Ministra Zdrowia z Dnia 17 Czerwca 2024 r. w Sprawie Wykazu Refundowanych Lek\u00f3w, \u015arodk\u00f3w Spo\u017cywczych Specjalnego Przeznaczenia \u017bywieniowego Oraz Wyrob\u00f3w Medycznych Na 1 Lipca 2024 r.\u2014Ministerstwo Zdrowia\u2014Portal Gov.Pl, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenie-ministra-zdrowia-z-dnia-17-czerwca-2024-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-lipca-2024-r."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International Uniform Response Criteria for Multiple Myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for Diagnosis, Staging, Risk Stratification and Response Assessment of Multiple Myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"ref_20","unstructured":"(2024, June 29). National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"ref_21","first-page":"10","article-title":"The WEKA Data Mining Software. ACM SIGKDD Explorations","volume":"11","author":"Hall","year":"2009","journal-title":"Newsletter"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1613\/jair.953","article-title":"SMOTE: Synthetic minority over-sampling technique","volume":"16","author":"Chawla","year":"2002","journal-title":"J. Artif. Intell. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.15433","article-title":"Infectious and Immunological Sequelae of Daratumumab in Multiple Myeloma","volume":"185","author":"Johnsrud","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ejh.13190","article-title":"Risk Factors for Infections in Newly Diagnosed Multiple Myeloma Patients: A Danish Retrospective Nationwide Cohort Study","volume":"102","author":"Klausen","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Nahi, H., Chrobok, M., Gran, C., Lund, J., Gruber, A., Gahrton, G., Ljungman, P., Wagner, A.K., and Alici, E. (2019). Infectious Complications and NK Cell Depletion Following Daratumumab Treatment of Multiple Myeloma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211927"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus Guidelines and Recommendations for Infection Prevention in Multiple Myeloma: A Report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103623","DOI":"10.1016\/j.critrevonc.2022.103623","article-title":"Management of Infectious Risk of Daratumumab Therapy in Multiple Myeloma: A Consensus-Based Position Paper from an Ad Hoc Italian Expert Panel","volume":"172","author":"Girmenia","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A Simple Score to Predict Early Severe Infections in Patients with Newly Diagnosed Multiple Myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.htct.2023.09.2362","article-title":"Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Uruguay","volume":"46","author":"Riva","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jung, S.H., Jang, H.C., Lee, S.S., Ahn, J.S., Yang, D.H., Kim, Y.K., Kim, H.J., and Lee, J.J. (2014). The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/413149"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3346\/jkms.2016.31.4.510","article-title":"Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-Based Regimens","volume":"31","author":"Hyun","year":"2016","journal-title":"J. Korean Med. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-2155-1","article-title":"Risk Factors and Characteristics of Blood Stream Infections in Patients with Newly Diagnosed Multiple Myeloma","volume":"17","author":"Huang","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Balmaceda, N., Aziz, M., Chandrasekar, V.T., McClune, B., Kambhampati, S., Shune, L., Abdallah, A.O., Anwer, F., Majeed, A., and Qazilbash, M. (2021). Infection Risks in Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials from 2015 to 2019. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08451-x"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3816\/CLM.2003.s.005","article-title":"The Implications of Anemia in Multiple Myeloma","volume":"4","author":"Mittelman","year":"2003","journal-title":"Clin. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1615\/CritRevOncog.2013007934","article-title":"Iron in Multiple Myeloma","volume":"18","author":"Vanderwall","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2010-03-274571","article-title":"In Anemia of Multiple Myeloma, Hepcidin Is Induced by Increased Bone Morphogenetic Protein 2","volume":"116","author":"Maes","year":"2010","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjh.14593","article-title":"Anaemia, Iron Deficiency and Susceptibility to Infection in Children in Sub-Saharan Africa, Guideline Dilemmas","volume":"177","author":"Jonker","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1042\/BCJ20210263","article-title":"Lactate Cross-Talk in Host\u2013Pathogen Interactions","volume":"478","author":"Llibre","year":"2021","journal-title":"Biochem. J."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Romero-Garcia, S., Moreno-Altamirano, M.M.B., Prado-Garcia, H., and S\u00e1nchez-Garc\u00eda, F.J. (2016). Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00052"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.thj.6200574","article-title":"The Effect of Iron Deficiency Anemia on the Function of the Immune System","volume":"5","author":"Ekiz","year":"2005","journal-title":"Hematol. J."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Oh, T.K., Song, K.H., and Song, I.A. (2021). History of Anemia and Long-Term Mortality Due to Infection: A Cohort Study with 12 Years Follow-up in South Korea. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06377-0"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-018-0205-5","article-title":"Late-Stage Tumors Induce Anemia and Immunosuppressive Extramedullary Erythroid Progenitor Cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2022.04.018","article-title":"Tumor-Induced Erythroid Precursor-Differentiated Myeloid Cells Mediate Immunosuppression and Curtail Anti-PD-1\/PD-L1 Treatment Efficacy","volume":"40","author":"Long","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2021-146035","article-title":"Early Infection Risk in Newly Diagnosed Multiple Myeloma Patients in the Modern Era","volume":"138","author":"Stevenson","year":"2021","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lin, C., Shen, H., Zhou, S., Liu, M., Xu, A., Huang, S., Shen, C., and Zhou, F. (2020). Assessment of Infection in Newly Diagnosed Multiple Myeloma Patients: Risk Factors and Main Characteristics. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05412-w"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A Predictive Model for Risk of Early Grade \u2265 3 Infection in Patients with Multiple Myeloma Not Eligible for Transplant: Analysis of the FIRST Trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00277-018-3401-y","article-title":"Low Frequency of CD3+CD4+CD161+ T Cells Correlates with the Occurrence of Infections in Refractory\/Relapsed Multiple Myeloma Patients Receiving Lenalidomide plus Low-Dose Dexamethasone Treatment","volume":"97","author":"Lee","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mikulski, D., Robak, P., Ry\u017cewska, W., Sta\u0144czak, K., Ko\u015bcielny, K., G\u00f3ra-Tybor, J., and Robak, T. (2022). Risk Factors of Infection in Relapsed\/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. J. Clin. Med., 11.","DOI":"10.20944\/preprints202209.0018.v1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4258\/hir.2016.22.3.186","article-title":"Interpretation of Clinical Data Based on C4.5 Algorithm for the Diagnosis of Coronary Heart Disease","volume":"22","author":"Wiharto","year":"2016","journal-title":"Healthc. Inform. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12911-019-0825-9","article-title":"Decision Tree-Based Classifier in Providing Telehealth Service","volume":"19","author":"Chern","year":"2019","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ilyas, H., Ali, S., Ponum, M., Hasan, O., Mahmood, M.T., Iftikhar, M., and Malik, M.H. (2021). Chronic Kidney Disease Diagnosis Using Decision Tree Algorithms. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02474-z"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-34906-1","article-title":"Application of Supervised Machine Learning Algorithms for Classification and Prediction of Type-2 Diabetes Disease Status in Afar Regional State, Northeastern Ethiopia 2021","volume":"13","author":"Ebrahim","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100245","DOI":"10.1016\/j.dajour.2023.100245","article-title":"A Comparative Assessment of Machine Learning Algorithms with the Least Absolute Shrinkage and Selection Operator for Breast Cancer Detection and Prediction","volume":"7","author":"Hassan","year":"2023","journal-title":"Decis. Anal. J."},{"key":"ref_54","first-page":"28","article-title":"Platelet Distribution Width: A Simple, Practical and Specific Marker of Activation of Coagulation","volume":"14","author":"Vagdatli","year":"2010","journal-title":"Hippokratia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.thromres.2022.10.001","article-title":"Step up to the Platelet: Role of Platelets in Inflammation and Infection","volume":"231","author":"Carestia","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an Intravascular Effector of Innate Immunity","volume":"13","author":"Engelmann","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pbj.2017.05.005","article-title":"Role of Platelets in Immune System and Inflammation","volume":"2","author":"Sonmez","year":"2017","journal-title":"Porto. Biomed. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2012-06-437392","article-title":"Platelet Serotonin Promotes the Recruitment of Neutrophils to Sites of Acute Inflammation in Mice","volume":"121","author":"Duerschmied","year":"2013","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood-2013-11-462432","article-title":"Emerging Roles for Platelets as Immune and Inflammatory Cells","volume":"123","author":"Morrell","year":"2014","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/09537100075760","article-title":"Shape Change in Human Platelets: Measurement with a Channelyzer and Visualisation by Electron Microscopy","volume":"11","author":"Jagroop","year":"2000","journal-title":"Platelets"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12672-024-01254-z","article-title":"Optimal Cut-off Values and Diagnostic Significance of Clinical Laboratory Indicators in Newly Diagnosed Multiple Myeloma","volume":"15","author":"Li","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3906\/sag-1803-87","article-title":"Evaluation of Platelet Parameters and Neutrophil\/Lymphocyte Ratio during Omalizumab Treatment in Patients with Severe Chronic Spontaneous Urticaria","volume":"48","author":"Avci","year":"2018","journal-title":"Turk. J. Med. Sci."},{"key":"ref_63","first-page":"3426878","article-title":"Utility of Tetrahydrobiopterin Pathway in the Assessment of Diabetic Foot Ulcer: Significant and Complex Interrelations","volume":"2019","author":"Ratha","year":"2019","journal-title":"J. Diabetes Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Hlap\u010di\u0107, I., Somborac-Ba\u010dura, A., Popovi\u0107-Grle, S., Dugac, A.V., Rogi\u0107, D., Rako, I., Grubi\u0161i\u0107, T.\u017d., and Rumora, L. (2019). Platelet Indices in Stable Chronic Obstructive Pulmonary Disease\u2014Association with Inflammatory Markers, Comorbidities and Therapy. Biochem. Med., 30.","DOI":"10.11613\/BM.2020.010701"},{"key":"ref_65","first-page":"334","article-title":"Could Platelet Indices Be New Biomarkers for Inflammatory Bowel Diseases?","volume":"17","author":"Dag","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5114\/reum.2022.120760","article-title":"The Relationship between Platelet Distribution Width and Disease Activity in Patients with Polymyositis","volume":"60","author":"Sargin","year":"2022","journal-title":"Reumatologia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5152\/eurjrheumatol.2014.140023","article-title":"New Platelet Indices as Inflammatory Parameters for Patients with Rheumatoid Arthritis","volume":"1","year":"2014","journal-title":"Eur. J. Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Xie, X., Yan, D., Liu, X., Wang, Y., Deng, Y., Yao, R., and Li, N. (2022). High Platelet Distribution Width Is an Independent Risk Factor of Postoperative Pneumonia in Patients with Type A Acute Aortic Dissection. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.984693"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3892\/etm.2016.3583","article-title":"Diagnostic Values of Red Cell Distribution Width, Platelet Distribution Width and Neutrophil-Lymphocyte Count Ratio for Sepsis","volume":"12","author":"Zhang","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1515\/cclm-2023-0625","article-title":"Platelet Distribution Width (PDW) as a Significant Correlate of COVID-19 Infection Severity and Mortality","volume":"62","author":"Ligi","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Li, X.T., Yan, Z., Wang, R.T., and Yu, K.J. (2019). Preoperative Mean Platelet Volume and Platelet Distribution Width Predict Postoperative Sepsis in Patients with Colorectal Cancer. Biomed. Res. Int., 2019.","DOI":"10.1155\/2019\/9438750"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/blood.V68.2.514.514","article-title":"Shortened Platelet Half-Life in Multiple Myeloma","volume":"68","author":"Fritz","year":"1986","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2264940","DOI":"10.1080\/09537104.2023.2264940","article-title":"Multiple Myeloma and Its Treatment Contribute to Increased Platelet Reactivity","volume":"34","author":"Mitchell","year":"2023","journal-title":"Platelets"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/09537100903360007","article-title":"Thrombopoietic Cytokines and Platelet Count in Multiple Myeloma","volume":"21","author":"Sucak","year":"2010","journal-title":"Platelets"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1158\/1078-0432.CCR-17-2003","article-title":"Platelets Enhance Multiple Myeloma Progression via Il-1b Upregulation","volume":"24","author":"Takagi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.clml.2024.05.020","article-title":"Association of Thrombocytopenia with Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Therapies","volume":"24","author":"Charalampous","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4314\/ahs.v23i2.22","article-title":"Predictive Value of Platelet-Related Parameters Combined with Pneumonia Severity Index Score for Mortality Rate of Patients with Severe Pneumonia","volume":"23","author":"Wang","year":"2023","journal-title":"Afr. Health Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wang, Y., Fan, Z., Wang, S., and Zhuang, C. (2021). The Diagnostic Value of Platelet Distribution Width in Patients with Mild COVID-19. J. Clin. Lab. Anal., 35.","DOI":"10.1002\/jcla.23703"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin Prophylaxis in Patients with Newly Diagnosed Myeloma (TEAMM): A Multicentre, Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5662\/wjm.v13.i5.373","article-title":"Challenges and Limitations of Synthetic Minority Oversampling Techniques in Machine Learning","volume":"13","author":"Alkhawaldeh","year":"2023","journal-title":"World J. Methodol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Yao, L., Wong, P.K., Zhao, B., Wang, Z., Lei, L., Wang, X., Hu, Y., Yao, L., Wong, P.K., and Zhao, B. (2022). Cost-Sensitive Broad Learning System for Imbalanced Classification and Its Medical Application. Mathematics, 10.","DOI":"10.3390\/math10050829"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ins.2020.07.014","article-title":"RCSMOTE: Range-Controlled Synthetic Minority over-Sampling Technique for Handling the Class Imbalance Problem","volume":"542","author":"Soltanzadeh","year":"2021","journal-title":"Inf. Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/21\/3709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:27:33Z","timestamp":1760113653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/21\/3709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":82,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cancers16213709"],"URL":"https:\/\/doi.org\/10.3390\/cancers16213709","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,3]]}}}